Clinical Use of CA 125 and Its Combination Assay with Other Tumor Marker in Patients with Ovarian Carcinoma

1987 ◽  
Vol 23 (3) ◽  
pp. 200-207 ◽  
Author(s):  
Yoshiyuki Negishi ◽  
Toshihito Furukawa ◽  
Takashi Oka ◽  
Masaru Sakamoto ◽  
Takao Hirata ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Tumor Marker ◽  
Ca 125 ◽  
Clinical Use

scholarly journals Diagnostic accuracy of PET/CT scan in evaluation of clinically suspected recurrent ovarian cancer

2021 ◽  
Vol 14 (4) ◽  
pp. 156-160
Author(s):  
Nimrah Sultana ◽  
Shaista Shoukat ◽  
Sadaf Nausheen ◽  
Bakhtawar Memon
Keyword(s):  
Ovarian Cancer ◽  
Diagnostic Accuracy ◽  
Ovarian Carcinoma ◽  
Ct Scan ◽  
Tumor Marker ◽  
Recurrent Ovarian Cancer ◽  
Ca 125 ◽  
Pet Ct ◽  
Suspected Recurrence ◽  
Pet Ct Scan

Background: Accurate evaluation of ovarian carcinoma is utmost important for effective management. PET/CT is reported to be effective in evaluation of suspected recurrence of ovarian carcinoma. This study aims to assess the accuracy of PET/CT in evaluation of recurrent ovarian cancer among clinically suspected cases with rising tumor marker or suspicious clinic-radiological findings. Patients and methods: This prospective cross-sectional study was conducted at Radiology department of Jinnah Postgraduate Medical Centre Karachi from 22nd April 2019 to 21st April 2020. Patients having age of 40 to 60 years and referred for PET scan with suspected recurrence of ovarian carcinoma were consecutively enrolled. Patients were suspected due to relevant history, clinical findings and initial imaging investigations with elevated CA-125 level. Results of 18FDG PET/CT scan was correlated with the raised tumor findings. The PET/CT scan showing abnormally elevated FDG take-up and higher SUV values than the background activity considered recurrence. Diagnostic accuracy of PET/CT was calculated taking raised tumor level as reference category. Results: Of 65 patients, median age was 50 (43-56) years. The findings showed positive cases in 57 (87.7%) while negative in 8 (12.3%) patients, whereas the findings of tumor marker showed raised tumor marker in 61 (93.8%) patients. Diagnostic accuracy of PET/CT showed sensitivity, specificity, positive predicted value, negative predated value, and overall diagnostic accuracy as 93.44%, 100%, 100%, 50%, and 93.85% respectively. Conclusion: A higher accuracy of PET/CT was observed in the diagnosis of recurrent ovarian cancer among clinically suspected cases, thus helping in devising an appropriate management plan by the treating physician.

scholarly journals Rational application of tumor marker CA 125 in gynecological oncology

2010 ◽  
Vol 63 (3-4) ◽  
pp. 195-199
Author(s):  
Srdjan Djurdjevic ◽  
Sanja Stojanovic ◽  
Marijana Basta-Nikolic ◽  
Marko Maksimovic
Keyword(s):  
Ovarian Carcinoma ◽  
Tumor Marker ◽  
Malignant Tumors ◽  
Single Case ◽  
Residual Tumor ◽  
Ca 125 ◽  
Gynecological Oncology ◽  
Upper Level ◽  
Ca 125 Antigen ◽  
The Moment

Introduction CA 125 determination started in 1981, when Bast et al. discovered monoclonal antibody OC-125 belonging to immunoglobulin G class (IgG1) using K?hler and Milstein's technique of hybridization. CA 125 antigen is produced in amniotic cells of the 7 week-old embryo, while in adults it can be detected in epithelium of most organs which originate from M?ller ducts. The upper level of referent values for CA 125 in serum is 35 U/mL and can be seen in about 99% of healthy people. Application of tumor marker CA 125 in gynecological oncology More than 83% of patients with epithelial ovarian carcinoma have elevated values of CA 125 higher than 35 U/mL at the moment of diagnosing the disease. In cases of ovarian carcinoma, preoperatively determined values of CA 125 in serum are correlated with the extent of the expansion of the disease , histological type of tumor and degree of differentiation of malignant cells. Elevated values up to 65 U/mL in serum can also be found in other malignant tumors (pancreas, breast, colon, bladder, lungs, liver) and in different benign diseases. The level of serum CA 125 after the surgery can indicate regression or progression of ovarian carcinoma in more than 90% of the patients who had had elevated values of CA125 prior to the surgery. Postoperative levels of CA 125 >35 U/mL in patients with no residual tumor and values >65 U/mL in those with residual tumor implants represent a separate prognostic factor in further course of the disease. Conclusion The importance of continuous determination of CA 125 tumor marker has to be adjusted to each single case.

Differential Diagnosis between Uterine Myoma and Endometriosis using CA 125 as a New Tumor Marker of Ovarian Carcinoma

2010 ◽  
Vol 12 (1) ◽  
pp. 99-103 ◽  
Author(s):  
Kentaro Takahashi ◽  
Satoshi Kijima ◽  
Kazuo Yoshino ◽  
Toshihiko Shibukawa ◽  
Fuminori Murao ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Ovarian Carcinoma ◽  
Tumor Marker ◽  
Uterine Myoma ◽  
Ca 125

Primary Peritoneal Tuberculosis with Ascites and Elevated CA 125 Mimicking Advanced Ovarian Carcinoma

2014 ◽  
Vol 05 (01) ◽  
pp. 18-20
Author(s):  
Z. Hrgovic ◽  
T. Kulas ◽  
D. Bursac ◽  
G.P. Rados ◽  
K. Bojanic
Keyword(s):  
Ovarian Carcinoma ◽  
Tumor Marker ◽  
Ca 125 ◽  
Peritoneal Tuberculosis ◽  
Advanced Ovarian Carcinoma ◽  
Diagnostische Laparoskopie

ZusammenfassungWeltweit nimmt die Zahl der atypischen Formen der Tuberkulose zu, einschließlich der Beckentuberkulose. Hauptsächlich wird dies in Entwicklungsländern beobachtet mit einer schlechten Gesundheitsversorgung und einer hohen HIV-Prävalenz. Die Beckentuberkulose ist selten und schwer zu diagnostizieren, da unspezifisch und es oft zu unspezifischen klinischen Manifestationen kommt. Symptome der Erkrankung können Malignitäten vortäuschen und werden oft für adnexale Tumoren gehalten, besonders bei Vorliegen einer Aszites. Häufig werden die Fehldiagnosen und Therapie-Entscheidungen verbunden mit verstümmelnden unnötigen chirurgischen Eingriffen. Die Diagnose folgt dann nach der Biopsie und Pathohistologie. Retrospektiv werden Malignitäten ausgeschlossen. Die diagnostische Laparoskopie mit Biopsie im Zielgebiet und PCR sind die grundlegenden Methoden für eine korrekte Diagnsotik. Wir stellen hier den seltenen Fall einer Patientin mit Beckentuberkulose vor, die sich mit Harninkontinenz, Aszites und erhöhtem Tumor-Marker CA-125 vorstellte, was zunächst zu der Fehldiagnose einer gynäkologischen Malignität führte. Wenn gynäkologische Symptome behandelt werden, muss auch an ein Beckentuberkulose gedacht werden, die gynäkologische Malignitäten vortäuschen können.

How to Overcome the Disturbing Effects of Human Anti-Mouse Antibodies (Hama) on in Vitro Assays

1997 ◽  
Vol 12 (1) ◽  
pp. 15-17 ◽  
Author(s):  
J.B. Oltrogge ◽  
R.P. Baum ◽  
K.N. Lema ◽  
B. Donnerstag ◽  
G. Hör
Keyword(s):  
Monoclonal Antibodies ◽  
Ovarian Carcinoma ◽  
Tumor Marker ◽  
Protein A ◽  
Diagnostic Value ◽  
In Vitro Assays ◽  
Ca 125 ◽  
Tumor Patients

The development of human anti-mouse antibodies (HAMA) is a common immune response in patients with ovarian carcinoma after repeated injections of murine anti-CA 125 monoclonal antibodies for immunoscintigraphy. As a tumor marker with significant diagnostic value CA 125 is routinely measured in the follow-up of tumor patients by immunoradiometric assays (IRMA) based on murine anti-CA 125 monoclonal antibodies. HAMA may cause false-positive findings in a CA 125-IRMA. In this report our group demonstrates a simple way of eliminating HAMA by protein A/G affinity chromatography allowing the reliable detection of the tumor marker CA 125 in the serum of patients with ovarian carcinoma.

Sign in / Sign up

Export Citation Format

Share Document